AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease

Live updates

1. 1h ago

   FDA Approves AbbVie Parkinson's Drug Juvmo

   The US FDA approved Juvmo (tavapadon), a once-daily oral medication for adults with Parkinson's disease. Juvmo is the first and only selective D1/D5 receptor agonist in its class. The drug showed significant improvements in motor symptoms and longer periods of symptom control during the Phase 3 TEMPO program. This approval represents the first product delivered from AbbVie's 8.7 billion dollar acquisition of Cerevel, which took place two years ago. Despite the approval, AbbVie management expects a slow start for the medication's market entry.

   Why it matters

   The approval validates a multi-billion dollar investment in Cerevel to expand AbbVie's neurology portfolio. As a first-in-class treatment, Juvmo introduces a new mechanism for managing Parkinson's motor symptoms. The drug's success is tied to its ability to provide prolonged symptom control compared to existing therapies.

   What is confirmed

   • The FDA approved Juvmo (tavapadon) for the treatment of adults with Parkinson's disease.
   • Juvmo is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson.
   • AbbVie acquired Cerevel for 8.7 billion dollars two years ago.
   • Juvmo is administered as a once-daily oral treatment.
   • The Phase 3 TEMPO program demonstrated that Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.

   Still unconfirmed

   • A Cleveland Clinic doctor led the development of this breakthrough treatment.
   • AbbVie management expects a slow start for Juvmo.

   What to watch next

   • Market adoption rates and initial sales figures for Juvmo
   • Clinical data on long-term efficacy beyond the TEMPO program
   Sources used for this update (24)

   1. fiercepharma.com — AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
   2. Reuters — US FDA approves AbbVie's drug for Parkinson's disease
   3. BioSpace — AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
   4. MedPage Today — Parkinson's Disease Gets New Treatment Approved
   5. Yahoo Finance — AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start
   6. FOX 8 News — FDA approves ‘breakthrough’ Parkinson’s treatment led by Cleveland Clinic doctor
   7. Crain's Chicago Business — AbbVie’s $8.7B Cerevel deal pays off with Parkinson’s drug approved for U.S. patients
   8. Ynetnews — New Parkinson’s drug approved in the US: What does it do differently?
   9. Medscape — FDA Approves First-In-Class Med for Parkinson's Disease
   10. WGN-TV — FDA approves Juvmo, a first-of-its-kind medication for Parkinson’s disease
   11. www.biospace.com — AbbVie wins FDA approval for Parkinson’s drug from $8.7B ...
   12. news.abbvie.com — U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's ...
   confidence 100%